Aescine

Quick links to important sections

Aescine

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aescine

Quick Facts: Aescine (Escin)

Property Description
Active Ingredient Escin (A standardized mixture of triterpene saponins)
Form Oral preparations, Topical preparations, Injectable solutions
Pharmacological Class Venotonic Agent, Vasoprotective, Capillary Stabilizing Agent
General Purpose Supports vascular integrity and reduces fluid leakage (edema)
Origin Natural product (Derived from horse chestnut seeds, Aesculus hippocastanum)

What is Aescine (Escin) and Its Origin?

Aescine, identified by its core component synonym Escin, is a complex phytomedicine classified as a mixture of triterpene saponins. This substance is naturally sourced, extracted specifically from the seeds of the horse chestnut tree (Aesculus hippocastanum). The most potent and pharmacologically active component within this standardized plant extract is the stereoisomer eta-Aescin, a feature considered critical to its overall mechanism.

Escin is a key agent in supporting venous health. Aescine's primary function is helping to strengthen blood vessels, supporting its widespread clinical recognition.

What Pharmacological Class Does Aescine Belong To?

Aescine is principally categorized as a Venotonic Agent and a Capillary Stabilizing Agent, placing it within the broader pharmacological group of Vasoprotectives. Its primary pharmacological role is structurally oriented: to reinforce the integrity and improve the function of the peripheral vasculature, including the capillaries and veins.

The core mechanism involves helping to reinforce the walls of the smallest blood vessels, reducing excessive permeability or "leakiness," and enhancing venous tone. This fundamental action provides the general benefit of mitigating the physical symptoms associated with compromised blood return. Aescine facilitates the stabilization of capillary walls, which helps reduce excessive fluid build-up in tissues (edema). This characteristic supports the use of the medicine for easing swelling related to vascular function.

Aescine Forms: Oral, Topical, and Injectable Preparations

The active Escin mixture is prepared for different routes of administration, allowing it to be used systemically or locally. It is commonly available as oral solid forms (tablets or capsules), as well as topical preparations (gels or ointments), and, in some contexts, sterile injectable solutions. These various dosage form(s) ensure the active agent is delivered efficiently, whether absorbed through the digestive system or applied directly to the site of concern, providing therapeutic flexibility.

What side effects are possible with Aescine?

Possible Side Effects and Safety Information for Aescine

The safety profile of Aescine, derived from Aesculus hippocastanum seed extract, is based on official government regulatory documents. The documented adverse reactions are typically mild and infrequent.

Documented Adverse Reactions by Frequency and System

Adverse reactions are classified by frequency, with most effects categorized as uncommon or rare in regulatory texts. The primary System-Organ Classes involved include:

System-Organ Class (SOC) Examples of Reactions
Gastrointestinal Disorders Nausea, stomach discomfort, upset
Skin and Subcutaneous Tissue Disorders Pruritus (itching), rash
Nervous System Disorders Headache, dizziness
Immune System Disorders Hypersensitivity reactions

Serious Adverse Reactions and Restrictions

Serious Adverse Reactions officially documented include severe hypersensitivity reactions, such as angioedema (severe allergic swelling), which require immediate attention.

Safety-Related Restrictions and Limitations:

  • Contraindications: Use is contraindicated in individuals with known hypersensitivity to Aescine or its excipients. Specific regulatory documents also cite contraindication in cases of severe renal failure.
  • Population-Specific Constraints: Use during pregnancy and lactation is generally not recommended due to insufficient data. Safety and use are also restricted in pediatric populations.

Contextual Safety Notes

The official labeling emphasizes the necessity to seek immediate medical consultation if signs of inflammation, sudden swelling of one or both legs, severe pain, or skin hardness occur or worsen, as these are conditions requiring prompt medical evaluation. The risk of bleeding may be amplified if Aescine is co-administered with anticoagulants or other similar medicinal products, a safety consequence noted in regulatory documents.

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory profile for Aescine (Escin) overdose is defined by the official status that no cases of overdose have been formally reported for the prepared medicinal product in regulatory documents. This lack of documented case data means that specific, established clinical syndromes or physiological findings related to Aescine overdose are not listed in the official prescribing information.

Documented Manifestations and Outcomes

Due to the absence of specific case reports, no distinct signs or symptoms are detailed in the official regulatory labeling. However, it is anticipated that a dose exceeding the recommended level could result in an increased likelihood of experiencing an undesirable effect. Official documents do not list specific serious or life-threatening cardiovascular or neurological outcomes directly associated with Aescine overexposure.

Required Emergency Actions and Management

If a suspected overdose occurs and any symptoms develop, the regulatory instruction is that medical advice should be sought. Management of any adverse event is mandated to include appropriate symptomatic and supportive treatment, administered as warranted by the patient’s clinical status. There is no specific antidote known for Aescine overdose listed in the official regulatory information, and no explicit requirements for continuous hospital monitoring or special considerations for specific populations are documented in the overdose sections.

Therapeutic Uses of Aescine

What Aescine Treats: Main Uses and Benefits

The primary therapeutic area for Aescine (Escin) is used in situations involving certain distressing symptoms associated with fluid imbalance. Its relevance is within conditions involving inflammatory or irritative processes, such as Chronic Venous Insufficiency (CVI), which includes symptoms like swollen legs, pain, heaviness, and cramps.

The medicine is commonly used to help with symptom clusters that may become intense or disruptive, including symptoms related to CVI, swelling (edema), and post-traumatic and post-operative soft tissue discomfort. This supportive role is relevant when supportive symptom management is appropriate.

Aescine may be part of symptomatic management used for conditions involving episodic or fluctuating manifestations, such as conditions where fluid buildup or swelling is prominent, and acute episodes involving localized soft tissue swelling and bruising (hematoma). It assists with maintaining functional stability and contributes to improved comfort during symptomatic periods.


Quick Fact: Relief for Vascular-Related Discomfort

Symptom Domain General Benefit
Heavy, Aching Legs Provides support that helps ease the overall symptom burden.
Swelling (Edema) Assists with maintaining functional stability by managing fluid buildup.
Acute Bruising/Swelling Supports the patient during difficult episodes by easing localized distress.

Eligibility and Restrictions for Use

Who Can and Cannot Use Aescine?

The population eligibility for Aescine (Escin) is strictly defined by regulatory documents, distinguishing between approved groups, restricted use, and absolute contraindications.

Eligibility Scope

Population Category Regulatory Status
Populations for whom use is allowed Adults and Elderly
Populations for whom use is not recommended Children under 12 years; Adolescents under 18 years; Pregnant women; Lactating women
Populations for whom use is contraindicated Patients with known hypersensitivity to the active substance (Escin) or to any excipient

Official Eligibility Statements

Use of Aescine is contraindicated for individuals with a history of hypersensitivity to the components. The medicine is not recommended for use in children and adolescents under 18 years of age due to a lack of established safety and efficacy data, nor is it recommended during pregnancy or lactation for the same reason. Use is established for Adults and the Elderly under standard conditions.

Condition-Specific Rule: Patients with pre-existing cardiac insufficiency or renal insufficiency must seek medical advice if they experience sudden swelling or severe symptoms while using Aescine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Map: Official Regulatory Information for Aescine

The official regulatory position for the standardized extract containing Aescine is defined by the authoritative monograph from the European Medicines Agency (EMA).


Interaction Scope

  • Medicinal product categories with documented interactions: None formally reported.
  • Specific interacting medicines (if explicitly listed): None formally reported.
  • Mechanistic basis of interactions (only if stated in label): No specific pharmacokinetic or pharmacodynamic mechanisms are formally reported as the basis for an interaction.
  • Timing-based interaction rules (if applicable): None required, as no interactions are formally reported.
  • Population-specific interaction notes (if applicable): None documented relating to altered drug-interaction severity in specific populations.
  • Interaction-related restrictions: None formally documented based on interaction risk.

Interaction Classifications (High-Level)

  • Interaction severity classification: Not applicable, as no interactions are formally reported.
  • Regulatory basis: European Medicines Agency (EMA) Herbal Monograph.
  • Interaction-context constraints: The regulatory document specifies that the absence of reported interactions applies to the official product for its use.

Resulting Interaction Structure

Official interaction statements:

  • The official regulatory document for Aescine reports that no interactions with other medicinal products or other forms of interaction are known or documented.
  • No specific contraindicated combinations are listed based on formal interaction risk.
  • The official labeling does not specify any requirements for the separation of administration (timing-based rules) with other substances.
  • Interactions with food, alcohol, supplements, or herbal products are not formally reported.

Connection to the overall interaction profile (3 sentences):

The official interaction structure for Aescine is strictly defined by the regulatory finding that no interactions are formally reported in the authoritative monograph. This status means the official document does not specify any interacting substances or resulting restrictions that would typically define a drug interaction profile. The regulatory basis establishes an absence of documented pharmacokinetic or pharmacodynamic interaction concerns.

Mechanism of Action

️ Capillary Stabilization and Anti-Leakage Mechanism

Aescine is a compound that acts on the microvascular barrier, exhibiting stabilizing activity on the endothelial cell membrane. It achieves this by reinforcing lysosomal membranes and inhibiting enzymes such as Hyaluronidase that contribute to the breakdown of the perivascular matrix. This action preserves the structural integrity of the vessel wall and its junctions, and is associated with a reduction in the capillary filtration rate and plasma protein extravasation into the tissue.


Modulation of Venous Tone and Outflow Dynamics

The molecule modulates the calcium ion ( Ca^2+) activity within the smooth muscle layer of peripheral veins and venules. This modulation increases the muscle's sensitivity to Ca^2+, resulting in a state of enhanced basal venous tone (venoconstriction). This physiological consequence creates a mechanism that opposes venous distension and promotes resistance to changes in hydrostatic pressure within the microcirculation.


Interruption of Local Inflammatory Cascades

Aescine also influences the inflammatory cascade by suppressing the activation of the central transcription factor, Nuclear Factor-kappa B ( NF-kappa B), which limits the subsequent expression of pro-inflammatory molecules. This interruption of the pathway is a mechanism that regulates molecular signaling that affects vascular permeability and barrier function.

Dosage and Administration Information

How to Use Aescine

Aescine (Escin) is characterized by specific administration routes, dosing patterns, and durations of use. The medicine is employed either systemically via oral forms or locally via cutaneous application.


Administration Routes and Dosage Patterns

The primary routes are oral and cutaneous (topical). Oral solid forms, such as gastro-resistant tablets or capsules, are intended for systemic use. Semi-solid preparations, including gels and ointments, are applied directly to the skin for local action.

Administration Route Standard Adult Dosing Regimen Frequency
Oral (Systemic) Standardized to 50 mg triterpene glycosides per dose Twice daily
Cutaneous (Local) Apply a thin layer to the affected area 1 to 3 times per day

Key Administration Instructions

Specific timing and population guidelines apply for use. Oral preparations are typically swallowed whole and taken immediately after food (post-meal). This timing is a characteristic condition for administration. In the event of a missed dose, a double dose is not taken to compensate.

Usage is generally designated for short-term use. For oral administration, if the condition persists or worsens after 2 weeks, consultation with a healthcare professional is recommended. The use of Aescine is not intended for individuals under the age of 18 years. No change in the standard dosage is required for older adults.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Aescine

Evidence for Symptoms of Chronic Venous Insufficiency (CVI)

The largest body of research for Aescine has examined conditions characterized by systemic or functional imbalance, such as the symptoms associated with Chronic Venous Insufficiency (CVI). The evidence available consists of numerous Randomized Controlled Trials (RCTs), and these trials have been synthesized in detailed Systematic Reviews and Meta-Analyses.

Researchers monitored objective physical measurements, such as measuring lower-leg volume and ankle/calf circumference to check for fluid changes. Alongside these, studies also explored how symptoms evolved in the observed populations, such as patient-reported pain intensity and overall feeling of heaviness. Research so far describes patterns observed in the studies where objective measurements may show change compared to a control group, and patients monitored subjective discomfort, with findings describing patterns related to their experience.

Studies on Acute Swelling and Bruising

Controlled Clinical Trials have evaluated Aescine for use in conditions associated with acute or disruptive episodes, specifically localized soft tissue swelling (edema) that may happen after an injury or following surgery. Research in this area often consists of smaller-scale Controlled Clinical Trials, which examined outcomes related to episodic or acute changes.

Studies focusing on visible bruising (hematoma) primarily looked at topical preparations and monitored things like the visual resolution of the bruise and associated tenderness over very short periods. However, this research base is much less extensive than that for CVI.

Long-Term Data and Uncertainties

For Aescine, long-term data are not fully established. The core evidence for CVI largely consists of trials with follow-up durations that were limited, typically lasting only up to 20 weeks. This means that there is limited information for long-term outcomes regarding the sustained observation of Aescine beyond this intermediate period.

Data for certain groups remain insufficient. For instance, there is very limited information available from high-quality studies on how Aescine was studied in older adults with multiple health conditions or in individuals with severe CVI. The overall evidence quality varies across studies, particularly for the acute swelling and bruising indications, where sample sizes were modest.

Frequently Asked Questions (FAQ)

Common questions about Aescine (FAQ)


Q: Can Aescine be taken at the same time as common vitamins?

According to the official regulatory documents, no interactions between Aescine and other medicinal products, supplements, or food are formally known or documented. This status indicates that Aescine may typically be used alongside common vitamins, but it is important to review all administration details provided by a healthcare professional.


Q: What are the most common reasons someone might stop taking Aescine?

Official instructions indicate that Aescine use is generally designated for short-term periods. Regulatory information indicates that consultation with a healthcare professional is necessary if the condition persists or worsens after a short period of use. Additionally, use should cease immediately if serious adverse reactions, such as severe allergic swelling (angioedema), are observed.


Q: What is the difference between Aescine and other similar supplements?

Aescine is officially classified as a Venotonic Agent and a Capillary Stabilizing Agent, derived from the extract of the horse chestnut seed. Its primary pharmacological role is to reinforce the integrity and improve the function of peripheral blood vessels. This classification places it within the broader pharmacological group of Vasoprotectives, which defines its specific therapeutic action.


Q: Are there any known interactions between Aescine and pain relievers?

Official regulatory documents state that no specific interactions with other medicinal products are formally reported. However, a safety note indicates that the risk of bleeding may be amplified if Aescine is used at the same time as anticoagulants or similar products that affect blood clotting. Official guidance notes that it is important to discuss all existing medications with a health professional.


Q: Is Aescine approved for use in all countries?

Drug approval is a process handled separately by the regulatory bodies in each country, such as the European Medicines Agency (EMA) or the Therapeutic Goods Administration (TGA) in Australia. The official authorization status and labeling for Aescine are thus defined by the specific health authority in the region where the product is marketed.


Q: Can Aescine affect my blood pressure readings?

Aescine is officially classified as a Venotonic Agent because it affects venous tone (the stiffness of veins and venules) and capillary function. Official regulatory documentation does not explicitly list changes to systemic blood pressure (arterial blood pressure) as a documented adverse effect.


Q: Is Aescine safe for people who have kidney issues?

Regulatory documents establish that use of Aescine is contraindicated (must not be used) in individuals who have severe renal failure (severe kidney problems). Official information may indicate that people with pre-existing kidney conditions, even if not severe, should discuss Aescine use with a health professional.


Q: Is it okay to take Aescine if I have a liver condition?

Liver conditions are not listed as a formal contraindication in core regulatory texts. Regulatory information on medicinal products often suggests that individuals with pre-existing organ conditions, such as a liver condition, should discuss use with a healthcare professional.


Q: Does Aescine interact with medications for diabetes?

The official regulatory documents state that no interactions with other medicinal products, including those used for chronic conditions like diabetes, are formally known or documented.


Q: What does official guidance say about Aescine and pregnancy?

Official guidance states that Aescine is not recommended for use during pregnancy or lactation (breastfeeding). This restriction is in place due to a lack of sufficient data establishing the safety and effectiveness for these populations.


Q: Are there different strengths of Aescine available?

Yes, different formulations and concentrations are documented, such as oral solid forms and topical preparations (like gels). For oral administration, the dose is officially standardized to a precise amount of the active component, known as triterpene glycosides, per dose.


Q: What are the ingredients in the Aescine product?

Aescine (Escin) is the active ingredient, which is a plant-derived substance from the horse chestnut seed. Official product labeling provides details about the active substance, Escin, and also lists the inactive ingredients (known as excipients) used to create the specific formulation, such as a tablet or a gel.


Q: What is the required purity level of Aescine in medicinal products?

Aescine is classified as a standardized extract. This means that regulatory documents mandate a fixed, minimum quantity of the active component—the triterpene glycosides—must be present in the final product to ensure consistency and quality, rather than focusing solely on overall purity.


Q: Does taking Aescine require any special monitoring by a doctor?

Routine or mandatory blood test monitoring is not typically specified in the regulatory documents. However, official labeling highlights that medical consultation should be sought if symptoms worsen or if signs of severe inflammation or sudden, unexplained swelling occur.


Q: Can Aescine cause problems with my stomach?

The most common documented adverse reactions related to the stomach include general nausea and feelings of stomach discomfort or upset. These effects are typically documented as mild and infrequent in regulatory texts.


Q: Is there a specific time of day that Aescine should be taken?

Official administration instructions stipulate that oral preparations must be taken immediately after food (post-meal). While this timing is required, no specific time of day, such as morning versus night, is mandated by the regulatory guidance.


Q: Is Aescine considered a vasodilator?

No. Aescine is officially classified as a Venotonic Agent and a Capillary Stabilizing Agent, meaning it helps to increase venous tone (the stiffness of the veins) and stabilize capillaries. This action promotes venoconstriction, which is a mechanism distinct from vasodilation (the widening of blood vessels).


Q: Is Aescine an NSAID or a type of steroid?

No. Aescine is classified as a Venotonic Agent and a phytomedicine, which means it is a medicinal substance derived from a plant (horse chestnut). It is not classified as an NSAID (non-steroidal anti-inflammatory drug) or a steroid.


Q: Can Aescine be purchased over the counter?

The regulatory status of Aescine varies depending on the country and the specific formulation (e.g., tablet or gel). In some jurisdictions, products containing the standardized extract are approved for over-the-counter (OTC) use, while in others, a prescription is required.


Q: Are there studies on Aescine's effectiveness compared to placebo?

Yes. Official regulatory reviews of the evidence base confirm that numerous Randomized Controlled Trials (RCTs) have been conducted. These studies typically compare the effects and outcomes of Aescine against a control group, which is often a placebo.


Q: Are there any known interactions between Aescine and herbal teas?

Official labeling states that no interactions with food, alcohol, supplements, or general herbal products are formally reported in the core regulatory documents.


Q: Does Aescine make you tired or sleepy?

The official adverse reaction list for the nervous system includes mild effects such as headache and dizziness. However, tiredness or sleepiness (somnolence) are not listed as documented common side effects in the regulatory texts.

How should Aescine be stored and disposed of?

How to Store and Dispose of Aescine (Escin)

Official regulatory documents define specific environmental and handling rules for storing and disposing of Aescine.

Storage Requirements

Condition Requirement
Environment Store in a dry, cool, and well-ventilated place.
Protection Keep away from heat and direct sunlight; avoid incompatible materials such as oxidizing agents.
Container The container must be kept tightly closed.
Access The product must be stored locked up to restrict access.

Disposal Instructions

Disposal must be conducted in accordance with local, regional, and national regulations, utilizing an approved waste disposal plant.

The product must not be flushed into surface water or the sanitary sewer system, and its release to the environment must be avoided.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aescine found in:

A-Z Index: